Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications Authors: Mostafa Meshref, Ahmed Salah Hussein, Sahar Ahmed Allam, Khaled Moghib, Hossam Younis, Nevin Shalaby Published: 2026 ABSTRACT AbstractMultiple sclerosis (MS) is a neurological inflammatory disease with a complex etiology involving the dysregulated immune system, chronic inflammation, and genetic susceptibility. Although the precise cause of MS is unknown, previous studies have found a strong link between MS and certain viral infections, leading researchers to speculate that viruses may play a role in MS pathogenesis by acting as environmental triggers. We present a comprehensive review of viral associations with MS, focusing on viruses with strong evidence for involvement in disease development, including members of the Herpesviridae family—such as Epstein-Barr virus, human herpesvirus 6, varicella-zoster virus, herpes simplex virus 1, cytomegalovirus, and SARS-CoV-2. Those viruses appear to modulate the neuro-immunological system in genetically susceptible individuals, leading to immune-mediated demyelination. Viral exposure is thought to represent an early initiating or permissive event that triggers downstream immune dysregulation, ultimately leading to MS onset in predisposed hosts. Additionally, they can cause latent infections with episodes of reactivation, which might be associated with relapsing presentation of MS. Several theories have been proposed to explain the viral etiology of MS, including molecular mimicry, virus-induced inflammatory response, autoreactive T- and B-cell activation, and increased susceptibility to antigenic exposure. Besides addressing the current knowledge gap, we also highlight future research directions for effective MS management, including developing experimental models and conducting clinical trials, identifying specific biomarkers, and investigating novel antiviral agents. An improved understanding of MS etiology and the role of viruses in its physiopathology may enable more targeted interventions and better treatment outcomes.Keywords: Multiple Sclerosis, Virus, Infection, Antiretroviral Therapy, Disease-modifying Therapy Introduction Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disorder of the central nervous system (CNS), affecting almost 2.8 million people around the globe. It is associated with a high societal economic burden [1]. Among young adults, MS is the primary cause of non-traumatic disability [2, 3]. MS is an immune-mediated disease caused by complex gene-environment interactions [4]. Besides its genetic susceptibility, the etiology of MS includes various environmental and lifestyle factors such as viral infections (such as Epstein–Barr virus [EBV]), gut microbiota, exposure to tobacco smoke and organic solvents, insufficient sun exposure or low vitamin D levels, and working late night shifts [5–8]. Current clinical practice divides MS into four phenotypes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), and secondary progressive MS (SPMS) based on medical history and clinical symptoms [9]. RRMS accounts for 85% of cases at disease onset. It is characterized by distinct attacks that may last from days to weeks, with significant recovery often occurring after the initial attack and neurological stability between attacks. Typically, 2% of RRMS patients will progress to SPMS annually, which is characterized by more aggressive and permanent symptoms, along with constant deterioration of function that is not linked to sudden attacks [10]. While PPMS accounts for 15% of cases, usually starting later in life (around 40 years old), and is characterized by lower attack frequency, decline in physical function, and rapid onset of motor disabilities [10]. In contrast, CIS was recently recognized as the first clinical presentation with inflammatory demyelinating symptoms suggestive of MS [11]. Literature search and study selection This manuscript is a narrative review that synthesizes key concepts, clinical evidence, and emerging perspectives on the association between viral infections and MS. Relevant publications were identified through targeted searches of major biomedical databases, including PubMed, Scopus, and Web of Science, using combinations of keywords related to the central themes of this review. Additional articles were identified through manual screening of reference lists of relevant publications and key review papers. Studies were selected based on their relevance to the specific themes/sections discussed in the manuscript, their methodological rigor, and their contribution to advancing understanding of the topic. Priority was given to influential primary studies, high-quality reviews, and recent publications that reflect recent developments in the field. The literature was reviewed iteratively by the authors. As the review progressed, additional sources were incorporated when they contributed novel conceptual insights or empirical findings relevant to the narrative synthesis. The process was considered sufficient when subsequent literature searches yielded studies that largely confirmed previously identified findings without adding substantial new information to the key themes addressed in the review. This approach allowed the authors to develop a focused synthesis of the most informative and influential literature while maintaining the interpretive and thematic nature of a narrative review. Pathogenesis of MS CNS white and gray matter tissue inflammation is the primary cause of damage in MS [8]. While the specific cause of this inflammation is still unclear, multiple studies have reported that the interaction between antigen-presenting cells (APCs) and CD8 + T lymphocytes plays an essential role in the initiation and progression of MS [12–14]. Environmental risk factors, such as vitamin D deficiency and cigarette smoking, are thought to modulate the immune response and may interact with viral exposures—particularly latent viral infections—to amplify immune dysregulation and promote autoreactive responses in genetically susceptible individuals [5, 7]. This interplay of risk factors and immune pathways provides a biologically plausible framework linking environmental influences on virus-mediated immune activation in MS. Pathogen-associated molecules bind to toll-like receptors on APCs, leading to the production of cytokines, including IL-12, IL-23, and IL-4. These cytokines induce CD4 + T cell differentiation into Th1, Th2, or Th17 phenotypes, which can release special cytokines. Pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF- α), IL-17, IL-21, IL-22, and IL-26 promote inflammation by suppressing Th2 differentiation and activating more cytokines [15]. Figure 1 shows T-cell immune interactions for MS pathogenesis. Role of T-Cells in Pathogenesis of Multiple Sclerosis. Th = T-helper, IL-4 = Interleukins-4, TGF-β = Transforming growth factor beta, IFN-α = Interferons alpha, IFN-γ = Interferons gamma Association between viral infections and MS The most common viral infections associated with MS include human herpesvirus 6 (HHV-6), EBV, and Mycoplasma pneumonia [16]. Other viruses associated with MS include Rabies, Parainfluenza virus 1, Simian virus 5, Human T lymphotropic virus 1 (HTLV-1), Multiple Sclerosis Associated Retrovirus (MSRV), Herpes Simplex Virus 1 (HSV-1), HHV-6, Borna Virus, COVID-19, and varicella-zoster virus (VZV) [16–19]. In recent years, the role of viruses in the pathophysiology of MS has gained considerable interest. Multiple epidemiological studies have highlighted the link between various viral infections and the development of MS [20]. Cermelli et al. reported a higher incidence of HHV-6 DNA detected by nested polymerase chain reaction (nested–PCR) among patients with MS compared to individuals with other neurological disorders [21]. The association between viral invasion and the development of MS has been previously examined, and it has been shown that the observed demyelination in MS precedes the invasion of antibodies and lymphocytes, suggesting a viral origin of the autoimmune components of the disease through the induction of initial neuronal damage and an autoimmune reaction [22–25]. Previous studies reported a decreased risk of MS among individuals who migrated from high-risk to low-risk regions, particularly when migration occurred before age 15 [26–28]. Two main hypotheses may explain this observation: first, early childhood infection might protect against later MS development; second, the disease may develop around age 15, with a prolonged latent period before clinical manifestation. This is not applied to the counteractive immigration from low-risk to high-risk regions, as it seems to be highly improbable that immigration from South Africa to Europe increases the risk of MS [29]. Impact of viral components on ms pathogenesis: animal and mechanistic viral models Several animal models of demyelination have been used to study the etiology of MS. The most popular ones include experimental autoimmune/allergic encephalomyelitis (EAE), virally induced chronic demyelinating disease (Theiler’s murine encephalomyelitis virus, or TMEV), and toxin-induced demyelination [30]. Theiler’s murine encephalomyelitis virus (TMEV), a natural pathogen of mice, is the most critical viral model for the study of MS. TMEV-induced demyelinating disease (TMEV-IDD) establishes an incessant infection comparable to the chronic form of MS [31]. The disease is biphasic, characterized by an early acute phase and a late chronic demyelinating phase. During the acute phase of TMEV-IDD, the viral antigen and genome invade grey matter neurons, accompanied by infiltration of various immune cells, including CD4 + and CD8 + T cells, monocytes, a few B cells, and plasma cells [32–34]. This results in CNS inflammation and reduced viral load. However, viral infection usually persists, leading to the progression to the chronic phase. During the chronic phase, TMEV persists in oligodendrocytes, astrocytes, microglia/macrophages, and inflammatory cells, including CD4 + and CD8 + T cells. Also, it persisted in a few macrophages, B cells, and plasma cells infiltrating the white matter, ultimately triggering demyelination and axonal damage [32–34]. Although TMEV-IDD is the best animal model for studying the viral hypothesis in MS, it has several limitations. Firstly, TMEV-IDD does not exhibit relapses and remissions like MS; instead, it has a disease course similar to that of PPMS. Furthermore, TMEV-IDD primarily affects the spinal cord and does not replicate the extent of brain damage observed in MS. Lastly, TMEV is structurally and functionally distinct from the HHVs associated with MS, which may lead to distinct immune responses [31]. The Semliki Forest Virus (SFV), a neurotropic virus belonging to the family togviridae, has been studied for B6 and SJL mice. It causes acute encephalomyelitis in both. The mean viral titer one week post-infection in B6 mice was 7.2 ± 0.38 (log10 TCID50), compared to 5.1 ± 1.20 (log10 TCID50) in SJL mice, resulting in more severe disease in B6 mice [35]. SFV antigen was found to be more abundant in the CNS tissue of B6 mice with a titer of 19.7 ± 6.7, while for 3.4 ± 1.2 in the SJL mice, indicating greater dissemination of the virus into the CNS of B6 mice [35]. In BALB/c mice, the inflammatory response and the subsequent lesions are reduced by administering anti-CD8 + antibodies [36]. Murine hepatitis virus (MHV) is another viral model used to study the development of pathogenesis of MS. Though the virus is eliminated after two weeks of intracranial injection into susceptible mice, viral antigen and RNA continue to persist in the oligodendrocytes, triggering the development of immune-mediated demyelinated disease with distinctive lesions identical to those in MS patients [37]. Macrophages, CD4+, and CD8 + cells have been implicated in the sequelae, leading to demyelination [37]. The Japanese Macaque Rhidnovirus (JMR), a gamma-2 herpesvirus, is a relatively new viral model for studying the pathophysiology of MS. JMR-based animal studies have identified lesions with immunological features comparable to those in active MS lesions [38]. Figure 2 shows the contribution of viral components to MS pathogenesis. Contribution of viral components to MS pathogenesis. TMEV-IDD= Theiler’s murine encephalomyelitis virus-induced demyelinating disease, SFV= Semliki forest virus, MHV= Murine hepatitis virus Different mechanisms may interact in various ways to enhance virus-induced demyelination. Specific lesions linked to MS were detected in a multicenter investigation, in which no evidence of invasion by autoimmune components, such as antibodies and the complement system, was observed [38, 39]. This indicates that, in addition to the well-known theory that MS pathogenesis is induced by virus-mediated autoimmune and inflammatory damage to the CNS, the virus may also have a direct toxic effect on CNS cells. Another mechanism by which T-cells are postulated to become autoreactive is mediated by molecular mimicry, in which host antigens are mimicked, leading to an autoimmune reaction against host tissues [39]. Hepatitis B virus (HBV) antigens and Myelin Basic Protein (MBP) have a similar amino acid sequence, so mice sensitized against HBV show reactivity for MBP [40]. Molecular mimicry is one of the mechanisms explaining the virally-induced demyelination, in which viral peptides share structural homology with myelin antigens, leading to cross-reactive T- or B-cell responses and autoimmunity. In contrast, bystander activation is cytokine-mediated activation of non-specific T cells, in which the body’s immune system becomes hyperactive to a virus, leading to the formation of new plasma cells and T lymphocytes, which damage body tissues [38]. Bystander activation is driven by a pro-inflammatory milieu, not by peptide specificity as molecular mimicry. A third mechanism is epitope spreading, first described by Lehmann et al. [41]. In this mechanism, the initial immune-mediated tissue damage/injury exposes sequestered self-antigens, leading to secondary autoimmune responses against additional myelin epitopes [42]. Similar peptide homology has been described for other viruses implicated in autoimmunity and immune evasion. Notably, Poxviridae and Herpesviridae (such as EBV nuclear antigen 1 [EBNA-1]) contain epitopes that cross-react with CNS antigens [43]. In addition, the U24 protein of HHV-6 exhibits sequence similarity to MBP, providing further support for molecular mimicry as a biologically plausible mechanism contributing to virus-induced demyelination [44]. These findings support molecular mimicry as a key immunopathogenic mechanism linking viral infections to MS. Epstein–barr virus (EBV; family: herpesviridae, genus: lymphocryptovirus, species: human gammaherpesvirus 4) and MS pathogenesis EBV is a ubiquitous virus that infects over 95% of the world’s population. Previous research on EBV has examined its role in MS development [45]. EBV seropositivity is more frequent among MS patients (approaching 100%) than in the general population (~ 65%) [45–47]. Recently, a Swedish case-control study suggested that EBV increases the risk of developing MS from a low risk in individuals under the age of 20 to a high risk in those aged 20–39 years [48]. However, serology-based epidemiological studies have some limitations: EBV seropositivity is highly prevalent in the general population, antibody titers do not reliably reflect viral activity or latency, and observed temporal associations do not establish causation. Therefore, while the increased frequency of EBV seropositivity among MS patients supports an association, it does not alone prove a direct pathogenic role in MS initiation or progression. A prospective study of patients with MS reported a remarkable increase in EBV antibody levels before the onset of MS [49]. However, a potential limitation of the study was the short interval between the blood tests and the onset of MS. Demyelination in autoimmune diseases may begin several months before neurological manifestations. Therefore, the increased serum levels of EBV antibodies could indicate the latent period of the disease [49]. In a longitudinal study by Bjornevik et al., 97% of EBV-negative participants in the MS group experienced seroconversion, compared with 57% in the control group, highlighting that the risk of MS increased 32-fold following EBV seroconversion. They also demonstrated that EBV infection preceded an elevation in serum neurofilament light chain levels in the MS group, suggesting that EBV infection is a leading cause of MS that occurs before the earliest signs of MS pathology [50]. Infectious mononucleosis increases the risk of MS, although the exact mechanism underlying this association remains unclear [51]. Findings hypothesize that a primary EBV infection increases blood-brain barrier (BBB) permeability, thereby facilitating this association [52]. Previous studies have indicated that EBV can persist and reactivate in ectopic B cell follicles that develop in the meninges of MS patients. These follicles are linked to significant cortical damage and more severe disease progression. The ectopic lymphoid structures likely serve as “immunoprivileged niches” for the virus, making them essential sites for immune evasion [53–57]. Several immune dysfunctions are associated with EBV in MS, including elevated EBV-specific antibody levels, impaired cytotoxic T cell (CTL) control of EBV infection, and evidence of molecular mimicry between EBV-encoded proteins and CNS autoantigens, including myelin basic protein (MBP), anoctamin-2 (ANO2), glial cell adhesion molecule (GlialCAM), and alpha-crystallin B (CRYAB), both for B cell antibodies and/or CD4 + T cells. EBV has a strong tropism for host memory B cells, which serve as APCs. After an initial lytic infection, the virus enters a latent phase, during which approximately 10 EBV-related latent proteins and RNAs are expressed in various latency programs (latency 0, I, II, and III), leading to the activation of autoreactive T cells that can damage myelin proteins. The proteins and RNAs involved include EBNA, latent membrane proteins (LMP), and EBV-encoded small RNAs (EBER) [58–62]. Additional support for the role of EBV in MS immunopathology comes from clonal expansion and persistence of EBV-infected B cells within the CNS meninges. Serafini et al. demonstrated that EBV markers were detectable in brain-infiltrating B cells and plasma cells in nearly all examined MS cases (21 of 22 patients), but not in other inflammatory neurological diseases [56]. Notably, ectopic B-cell follicles in the cerebral meninges of patients with SPMS were identified as major reservoirs of EBV, where latent viral proteins were consistently expressed and viral reactivation was observed. These meningeal aggregates were associated with local activation of cytotoxic CD8⁺ T cells, suggesting ongoing immune surveillance and tissue damage. Although it remains unclear whether CNS homing of EBV-infected B cells represents a primary pathogenic event or a secondary consequence of chronic inflammation, these findings support the concept that localized EBV persistence, clonal B-cell expansion, and episodic reactivation within the CNS may contribute to sustained immune activation and disease progression in MS [56]. In latency phase II, three proteins—EBNA1, EBNA2, EBNA3, EBNALP, LMP1, and LMP2—are expressed. It is divided into phase IIa, which occurs in germinal center cells and various EBV-associated malignancies such as Hodgkin lymphoma, NK/T-cell lymphoma, and nasopharyngeal carcinoma, and phase IIb, which is often seen during early post-infection periods in vitro and in primary infected B cells from chronic lymphocytic leukemia patients [60, 61]. During the latency phase III of EBV, six EBNA proteins and three LMP proteins are expressed. In vitro, this process allows EBV to transform primary B cells into continuously proliferating lymphoblastoid cell lines. However, in vivo, cells in latency III are at a higher risk of elimination due to their strong immunogenicity, which provokes an EBV-specific T-cell response [60, 61]. In MS, data suggest poor control of EBV latency, especially in the active phase of the disease, leading to elevated expression of the lytic gene and heightened inflammation [63]. Rand et al. concluded that Oligoclonal Bands (OCBs) targeting EBNA-1 were detected in the cerebrospinal fluid (CSF) of 5 of 15 MS patients, compared with none in the 12 controls [64]. Moreover, Virtanen et al. found that 38% of MS patients had OCBs that were reactive to HHV-6 and EBV antigens [65]. This could be explained by molecular mimicry [66]. Lanz and his colleagues have also observed that clonally expanded B cells produce anti-EBNA1 and anti-GlialCAM antibodies within the CNS of MS patients, supporting molecular mimicry as the mechanistic link between MS and EBV infection [67]. Sattarnezhad et al. demonstrated that antibody responses against EBNA1, GlialCAM, CRYAB, and ANO2 are increased in MS patients, with anti-EBNA1 and anti-GlialCAM antibodies significantly increasing MS risk in an additive manner. Furthermore, antibody reactivity against ≥ 1 EBNA1 peptide and CNS-mimic increases MS risk modestly but significantly [68]. More recently, Hohendorf et al. found a more diverse repertoire of MHC-I–restricted EBV-specific TCRβ sequences in MS patients, suggesting the presence of a wide array of EBV-specific CD8 + killer T cells [69]. Despite serologic data associating EBV infection with MS, there is no evidence of EBV infection in MS patients’ brains [70]. Hilton et al. examined 21 lesions in 10 brains and could not detect viral mRNA in any of the lesions [71]. Another study found a higher percentage of EBV in controls than in people with active MS [72]. These findings exclude an association between EBV infection and the pathogenesis of MS. Vaccination against EBV by targeting the gp350 viral protein has been associated with a decreased incidence of MS [14, 73, 74]. Vaccination against EBV reduces the likelihood of contracting infectious mononucleosis, thereby lowering the risk of developing MS. The concept of developing a preventive vaccine to eliminate EBV infection and the associated MS relies on either neutralizing the virus with antibodies or enhancing cell-mediated immunity to clear persistently infected cells [75]. Following this rationale, the depletion of EBV-infected B cells using purine analogs, such as rituximab (Anti-CD20), might be suitable for MS patients [76]. Rituximab treatment has been linked to fewer relapses and brain lesions caused by the inflammatory response in people with MS [77]. However, there are several disadvantages to using rituximab in MS patients and, therefore, it should be utilized with caution [73]. The injection of CD8 + T lymphocytes specific for EBV has been shown to reduce the illness and diminish intrathecal immunoglobulin synthesis. The efficacy of this treatment led to phase I clinical trials in which patients with progressive MS received autologous CD8 + cell therapy, with promising outcomes [78]. Boosting immunity by administering autologous CD8 + cells, vaccinating with the gp350 viral antigen, or administering antibodies against gp350 limits disease progression in patients who develop MS after EBV infection [79]. Acyclovir reduces recurrence rates by 34% in patients with relapsing MS [80, 81]. Treatment with Valaciclovir also reduces the number of active disease lesions on magnetic resonance imaging (MRI) in patients with RRMS [81]. Therefore, antiviral therapy may be curative when EBV infection is suspected in the CNS of MS patients [78]. The role of EBV in MS pathogenesis is explained in Fig. 3. The role of EBV in MS pathogenesis. EBV= Epstein-Barr virus, MHC= Major histocompatibility complex, IFN-γ = interferon-gamma, TNFα = Tumor necrosis factor-alpha, IL-2 = Interleukin-2 Human herpesviridae and MS virus Cytomegalovirus (CMV; Family: Herpesviridae, Genus: Cytomegalovirus, Species: Human betaherpesvirus 5) CMV is a member of the Herpesviridae family that widely affects the global population, with early infections in infancy or adulthood [74]. CMV prevalence varies by race, socioeconomic status, age, and sexual behavior [82]. Similar to MS, the incidence of CMV infections is higher among females [83]. Although most CMV infections are asymptomatic, the primary disease is a syndrome mimicking infectious mononucleosis. Unfortunately, CMV can become a latent infection for life, continuing sporadically to shed from the pharynx and be excreted in the urine for years. Recent studies have suggested an association between CMV infection and the emergence and pathogenesis of various autoimmune disorders via molecular mimicry, as evidenced by increased IgG antibody titers in those patients [84]. The correlation between CMV and MS is controversial [82, 85–87]. However, Sundqvist et al. reported a negative association between MS and CMV serostatus, with an estimated OR of 0.73 (0.58–0.92; 95% CI) [86]. Additionally, the meta-analysis by Thakolwiboon et al. showed a negative association between MS and CMV IgG seropositivity, with variable seroprevalence across geographic regions [88]. The seroprevalence of CMV IgG among MS patients was significantly higher in the Middle East region (OR = 5.089; 95%CI: 01.067–24.263) and lower in Europe (OR = 0.750; 95%CI: 0.599–0.940) [88]. Another study reported a significant negative association between CMV serostatus and MS risk in a large presymptomatic cohort [89]. The study also highlighted additive interactions between serostatus for the EBV antigen EBNA-1 peptide and HHV-6 A and the risk of MS development, underscoring their role in disease pathogenesis. These findings highlight the importance of the interplay of several genetic and environmental factors as potential modifiers of the association between MS and CMV. There is well-established bidirectional evidence supporting the association between CMV exposure and MS development. The interaction between myelin oligodendrocyte glycoprotein (MOG) and CMV antigens has been identified in rodents and non-human primates [90]. In patients with MS, CMV has been detected in the demyelinating plaques and has been shown to contribute to demyelination among immunodeficient patients [91]. It can exacerbate autoimmune diseases like MS by increasing the CD4(+)CD28(-) T-cell population, thereby contributing to their pathogenesis. In contrast, CMV suppresses innate and adaptive immune mechanisms, and chronic CMV infection has been shown to differentiate and expand CD94 + NK2C+ natural killer (NK) cells, a phenotype associated with a reduced risk of MS progression. Furthermore, CMV-seropositive MS patients have higher levels of transitional B cells and lower levels of memory B cells and pro-inflammatory cytokines than seronegative patients [89]. The reduction in MS risk among CMV-seropositive patients is hypothesized to be mediated by immune competition between CMV and EBV or by the expansion of mature NK cells induced by latent CMV, thereby modulating the immune response to EBV [89, 92, 93]. Varicella–zoster virus (VZV; family: herpesviridae, genus: varicellovirus, species: human alphaherpesvirus 3) VZV is a neurotropic virus from the herpesvirus family that is highly contagious during childhood, causing either varicella (chickenpox) or herpes zoster (shingles). VZV can remain latent in the sensory ganglia and be reactivated during immunosuppression [94, 95]. The history of VZV and exaggerated immune response was observed to be more prevalent among MS patients [96, 97]. Several epidemiological studies have detected VZV DNA in the CSF and peripheral blood of MS patients [98]. In addition, VZV DNA levels were higher in MS patients during relapses and decreased during periods of clinical remission [99, 100]. In patients with progressive MS, the levels of VZV DNA were lower than those observed during disease relapses but higher than those found during remission [101]. It is hypothesized that VZV reactivation induces autoimmunity, resulting in demyelination and MS exacerbation. Additionally, VZV may trigger an autoimmune response through molecular mimicry, as it shares reactivity with the E and mutant forms of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), which plays a crucial role in the processing and transport of mRNA and pre-mRNA. This interaction could lead to neurodegeneration and the development of RRMS [96, 102, 103]. However, demyelinating-inflammatory diseases are rarely documented as complications in primary VZV infection and VZV reactivation [104]. Despite fingolimod being approved as the primary therapy for MS, accumulating evidence indicates that it reduces sphingosine 1-phosphate (S1P) receptor levels, thereby decreasing the migration of CCR7 + lymphocytes, lowering VZV-specific immunity, and reactivating VZV [96, 105]. Therefore, it remains unclear whether VZV contributes to the pathogenesis of MS or if it is merely incidental, related to the disease itself or its treatments. Herpes simplex virus type 1 (HSV-1; family: herpesviridae, genus: simplexvirus, species: human alphaherpesvirus 1) HSV-1 is another neurotropic virus belonging to the subfamily Alphaherpesvirinae of the Herpesviridae family, one of the most prevalent human viral pathogens. Primary infection with HSV-1 may cause a broad spectrum of clinical manifestations ranging from mild labial and oral lesions to severe conditions such as herpes simplex encephalitis and herpes simplex keratitis [106]. Numerous clinical and animal studies have suggested an association between HSV-1 and MS. Post-mortem studies have confirmed the presence of HSV-1 in the brains of MS patients, especially in active plaques [107]. However, interpretation of post-mortem viral transcript data is limited by RNA degradation, variable post-mortem intervals, tissue handling techniques, and sampling bias, which may affect the sensitivity for detecting viral RNA and complicate distinctions between latent, activated, or inactivated viral presence [108, 109]. Further evidence from newly diagnosed RRMS patients indicates that HSV-1 reactivation may be associated with disease activity, and that both HSV-1 DNA and IgG antibodies were detected in peripheral blood during acute attacks [110, 111]. A genetic study showed that the risk of MS was increased among pediatric patients with HSV-1 seropositivity and without the HLA-DRB1*15 allele [112]. A recent study found that asymptomatic HSV-1 infection via intranasal inoculation exacerbated a mild form of EAE. The authors highlighted that asymptomatic reactivations may occur at a high rate, eliciting host inflammatory responses to viral infection in the CNS and thereby contributing to disease onset and severity [113]. They observed persistent immune infiltration of the brain and spinal cord, with elevated levels of IL-6, TNF-α, and IL-1β mRNA, suggesting that chronic inflammation can accompany latent, asymptomatic HSV-1 infection [113]. Furthermore, Martin et al. demonstrated that HSV-1 reactivation may induce upregulation of several neuroinflammatory markers (toll-like receptor-4, interferon α/β, and p-IRF3) and neurodegenerative markers (phospho-tau and TauC3) in the CNS of asymptomatic animal models, suggesting that repeated reactivations may be linked to cumulative neuronal dysfunction [114]. Repeated HSV-1 intracerebral or subcutaneous inoculations have shown clinical and histological evidence of inflammatory EAE that resembles MS in animal models [115]. Accumulating evidence in animals suggests a potential association between HSV-1 and demyelination. Kristensson and her colleagues have demonstrated that latent internasal HSV-1 infection disrupts myelin sheaths, induces inflammatory cell infiltration, and leads to macrophages loaded with myelin degradation products in the trigeminal ganglia [116]. Latent HSV-1 infection of the brain was also associated with elevated concentrations of the matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), contributing to partial breakdown of the BBB and to the accumulation of senescence biomarkers in the CNS, promoting autoimmunity, which are essential factors in the pathogenesis of MS [117–119]. Additionally, previous studies showed that HSV-1 brain infection is characterized by early infiltration of macrophages and neutrophils into the brain [120, 121]. While macrophages secrete TNF-α, microglial cells produce IL-1β, which together influence BBB permeability, increase endothelial cell adhesion molecule expression, and promote infiltration of inflammatory immune cells [122]. Notably, nonproductive microglial infection with HSV-1 can also induce the expression of proinflammatory molecules, including IL-6, IL-8, CCL5, and CXCL10 [123]. Additionally, T cells were found to be the primary leukocyte cell type infiltrating the brain after HSV-1 infection and persist without detectable viral replication [120, 121]. These cells express IFN-γ and have been linked to increased neurodegeneration and demyelination in the brain [124]. However, other reports reported conflicting results and did not find a significant difference in HSV-1 DNA or IgG antibodies between adults with or without MS. Mowery et al. also found no significant association between prior HSV-1 infection and developing MS among pediatric patients [100, 125–129]. Thus, a clear relationship between HSV-1 and MS has yet to be established, and further investigations are required to elucidate HSV-1’s role in MS. Human herpesvirus 6 (HHV-6 A/6B; family: herpesviridae, genus: roseolovirus, species: human betaherpesvirus 6 A/6B) HHV-6 is another herpesvirus strongly associated with MS progression [130]. The role of HHV-6 in the pathogenesis of MS is controversial, and current evidence suggests it plays a role in MS progression rather than in its induction. Therefore, further investigation is warranted. Two main serotypes of the virus have been identified: HHV-6 A and HHV-6B. The former was shown to have more neurotropism and a stronger association with MS [131, 132]. HHV-6 infection is mediated by the complement inhibitor CD46, a cell-surface protein expressed on all nucleated cells, thereby allowing the virus to infect a wide range of host cells, including CNS cells. Whereas HHV-6B uses CD134, a primarily T cell surface protein, as a primary receptor [133]. The primary HHV-6 infection is typically asymptomatic, and the virus may persist in a latent state. According to a study of 77 MS patients, 21% demonstrated a significant intrathecal IgG response to HHV-6, with higher IgG levels, suggesting that HHV-6 IgG is more typical of MS than other neurological disorders [134]. However, this finding is questionable because HHV-6 antibodies can interact with other viruses, as at least one other Ig response to a different viral infection was also observed in these patients’ CSF [135]. Many adults continue to harbor antibodies against HHV-6 throughout their lives. Therefore, detecting serum IgG levels might not be reliable for diagnosing recent HHV-6 infection. Other diagnostic methods, such as quantification of viral DNA in CSF, are recommended to confirm HHV-6 infection and to study its role in MS [136, 137]. The role of HHV-6 in MS remains controversial, with studies reporting heterogeneous and sometimes conflicting results. Many studies have found significantly higher levels of HHV-6 IgG or IgM in MS patients compared to control groups. In contrast, other studies have observed no differences, especially when using specific recombinant antigens or during remission phases, highlighting critical methodological limitations of serology-based assessments [138, 139]. Intrathecal immune responses against HHV-6 have been detected in a subset of MS patients. Still, these responses often occur with polyspecific antiviral antibody production, suggesting nonspecific B-cell activation rather than a virus-specific pathogenic role in most cases [134]. Similarly, detection of HHV-6 DNA in serum or CSF yielded inconsistent results. While some studies reported high levels of cell-free HHV-6 DNA—particularly in SPMS—many others failed to detect viral DNA in blood or CSF, and positive PCR results were often comparable to those observed in other inflammatory or immunocompromised conditions [140–142]. More recently, large seroepidemiological studies using variant-specific antigens have suggested a differential role for HHV-6 variants, with HHV-6 A only showing a positive association with MS risk and a biological interaction with EBV, influenced by HLA genotype [143]. A longitudinal cohort study that followed MS patients for five months found that blood HHV-6 DNA levels were higher around the time of relapse (i.e., correlating with disease activity), further supporting the assumption of a dose-dependent association between HHV-6 IgG titer and the risk of relapse, with the titer peaking two weeks before relapse [144]. Overall, the existing literature supports a context-dependent, heterogeneous association between HHV-6 and MS, highlighting the need for standardized assays, variant-specific analyses, and longitudinal CNS-focused studies. Elevated HHV-6 immunological markers may also be a significant risk factor for MS progression. Tejada et al. observed that 50% of the activated T cells in MS were also active against HHV-6 [145]. Thus, it is thought that the U24 protein of HHV-6 shares residues with MBP, and that molecular mimicry was hypothesized to explain the interaction between MS and HHV-6 [145]. Furthermore, Chaollner et al. detected HHV-6 proteins in the brains of 70% of MS patients, compared with none in the control group, suggesting that HHV-6 can affect the reproductive capacity of glial precursor cells and subsequent myelin production [146]. Serological methods are valuable for distinguishing between acute and convalescent HHV-6 infections and for assessing HHV-6 seroprevalence. Both enzyme-linked immunosorbent assays (ELISA) and indirect fluorescent antibody tests are used to detect host IgM and IgG antibodies directed against HHV-6 [147]. Although PCR and serology are the primary methods for detecting HHV-6, substantial challenges remain. For instance, current serological assays cannot distinguish between HHV-6 A and HHV-6B, resulting in high rates of false-positive results. Furthermore, the lack of standardization among these assays impedes cross-laboratory comparison of findings, and ELISA-based assays often yield qualitative results that are not useful for clinical decision-making. Finally, this approach has limited utility among immunocompromised patients due to their impaired immunity; thus, their findings may not meet the threshold for active HHV-6 infection [147]. Although PCR is highly specific and sensitive, with a rapid turnaround time that enables early, prompt diagnosis and management, it still has several limitations. Firstly, it lacks the ability to differentiate active and latent HHV-6 infection; secondly, it lacks standardization among laboratories for comparison of results; and finally, it is developed for only specific specimen types [147]. The mechanism discussed with CMV (i.e., the immune competition between HHV and EBV) might explain the interaction between CMV and HHV-A6. Therefore, the immunological interaction between CMV and EBV, or HHV-A6, might explain the observed reduction in MS risk among CMV-seropositive patients [89]. The relationship between HHV-6 and MS is explained in Fig. 4. The relationship between Human Herpesvirus 6 and Multiple Sclerosis. HHV-6 = Human herpesvirus 6, DNA= Deoxyribonucleic acid, MS= Multiple sclerosis, IgG= Immunoglobulin G, MBP= Myelin basic protein West nile virus (WNV; family: flaviviridae, genus: flavivirus, species: west nile virus) and MS West Nile Virus (WNV) is a zoonotic, mosquito-borne flavivirus belonging to the Japanese encephalitis virus complex [148]. The majority of WNV infections are asymptomatic. However, approximately 25% of infected patients may experience acute febrile symptoms or West Nile non-invasive disease, and fewer than 1% may develop West Nile neuroinvasive disease (WNND) [149]. WNND can manifest as encephalitis, meningitis, flaccid paralysis, altered consciousness, or seizures and may progress to permanent disability, especially among the elderly and immunocompromised patients or those with debilitating conditions such as diabetes, hypertension, chronic renal disease, and cancer [150–153]. Recently, multiple case reports were published linking MS with infection with WNV. Bui et al. presented a case of a young female with a previous history of WNV meningoencephalitis with a subsequent diagnosis of MS four years later [154]. Thebault et al. reported four cases of MS treated with anti-CD20 (Ocrelizumab) and diagnosed with neuroinvasive WNV infection [155]. No clinical or radiological factors affected the risk or severity of WNV infection. However, the authors found that anti-CD20 therapies might reduce the sensitivity of serologic testing for WNV among MS patients, and a high index of suspicion might be warranted [155]. Another case series has demonstrated that patients with MS and evident WNV infection may improve over time with intensive treatment, with reversible disability [156]. However, those with longer disease duration of MS, longer duration of therapy with anti-CD20, and more severe WNND had worse functional outcomes following inpatient rehabilitation [156]. Several hypothesized mechanisms might explain the association between WNV and MS. WNV induces neuronal degeneration by activating pro-inflammatory cytokines, such as IFN-γ, which are neurotoxic, and by promoting the accumulation of misfolded proteins in neurons, ultimately leading to neuronal apoptosis [157]. Subsequent apoptosis triggers microglial phagocytosis and astrocyte recruitment, leading to the accumulation of microglial nodules and reduced neurogenesis. Therefore, WNV may lead to neuronal degeneration and white-matter plaque accumulation, which are associated with MS development [157]. Another possible mechanism is that WNV might invade the CSF, triggering inflammation and damage to the anterior horn of the spinal cord. This inflammation may trigger or alter the immune response, leading to myelin damage and MS development [154, 158]. Further analysis could provide insights into the relationship between WNV and MS. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family: coronaviridae, genus: betacoronavirus, species: severe acute respiratory syndrome–related coronavirus) and MS pathogenesis The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19), has been shown to be more contagious than the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) [159]. About 7 million deaths and 704.7 million cases have been documented globally as of its last update on Apr 13th, 2024 [160]. COVID-19 patients have a heterogeneous presentation ranging from asymptomatic to severe, rapidly progressive, with reduced survival rates [161, 162]. Additionally, it can lead to acute respiratory distress syndrome (ARDS) and a heightened mortality risk induced by the viral activation of the immune system and induction of a cytokine storm [163, 164]. The main risk groups for severe COVID-19 include the elderly, patients with chronic diseases, and Black/African Americans [164]. SARS-CoV-2 can invade the brain by interacting with angiotensin-converting enzyme-2 (ACE-2), which is expressed along the BBB cerebrovasculature via its spike glycoprotein, leading to the induction of a pro-inflammatory response in endothelial cells, disruption of the BBB, and increased BBB permeability [165–167]. This is mediated by endothelial cells increasing the expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and MMPs, resulting in increased leukocyte adhesion and permitting the invasion of inflammatory cells (Fig. 5) [166, 167]. The relationship between COVID-19 and MS. SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2, ACE-2 = Angiotensin-converting enzyme-2, BBB= Blood-brain barrier The systemic inflammatory response and vascular injury caused by COVID-19 have the potential to exacerbate BBB breakdown and worsen MS progression [168]. Although several studies detected COVID-19 among relapsing MS patients [169, 170], only one reported detecting SARS-CoV-2 in CSF [171]. In these cases, there was no MRI-confirmed evidence of recurrence; the impairment was mildly aggravated, and all patients recovered fully. Therefore, the infection might be a precipitating factor for MS rather than a direct sequel of the infection itself. Future research is required to determine if there is a direct association between COVID-19 and MS [172]. Despite reports confirming the safety of SARS-CoV-2 vaccines, vaccine hesitancy remained a significant concern among MS patients [173]. A comprehensive meta-analysis involving 14,755 MS patients who received 23,088 doses of various SARS-CoV-2 vaccines found that the risk of relapse after vaccination was rare, occurring in only 1.9% of MS patients. The risk was lowest after the third vaccine dose, and no significant difference was observed by vaccine type. The authors emphasized that half of the vaccinated individuals reported adverse events, but they were generally mild and self-limiting [174]. Booster doses of the SARS-CoV-2 vaccine enhanced both humoral and cell-mediated immune responses among MS patients by increasing CD4 + and CD8 + terminally differentiated effector memory cells, as well as CD4 + effector memory cells, except for those treated with fingolimod and anti-CD20 therapies. Additionally, the vaccine appeared to impair IL-2 production, which may explain the absence of worsening symptoms following vaccination [175–177]. The association between disease-modifying therapies and MS There are several therapeutic options for MS with various mechanisms of action. Glucocorticoids and plasmapheresis can be used for the short-term management of acute MS relapses. On the other hand, disease-modifying therapies (DMTs) can be used for long-term immune modulation or inhibition, reducing the development of new CNS lesions, preventing relapses, and slowing MS progression [178, 179]. DMTs can be classified by their mechanisms of action into (1) immunomodulation, such as interferon-beta-1(IFN-β1) and glatiramer acetate (GA); (2) cell depletion, such as anti-CD20 antibodies, including rituximab, ocrelizumab, and anti-CD52 antibodies such as alemtuzumab; (3) cell trafficking alterations molecules: such as S1P receptor modulators such as fingolimod and natalizumab which prohibits the autoreactive T-lymphocytes trafficking across BBB; and (4) systemic immunosuppression such as teriflunomide [178, 179]. Disease-modifying therapies and antiviral mechanisms in virus-associated MS Memory B cells are the primary EBV reservoirs [180]. Here, multiple MS drugs target EBV virus-associated MS. For example, anti-CD20 drugs such as ocrelizumab reduce the number of memory B lymphocytes or inhibit their migration into the CNS [180–182]. Teriflunomide may impede lytic EBV infection by blocking the early phases of viral reactivation and inhibiting viral DNA replication through its effects on the host pyrimidine metabolism [183]. Leflunomide, a prodrug that is rapidly converted into teriflunomide in vivo, impairs B-cell functionality by reducing B-cell proliferation and delaying progression into the S phase in a non-selective manner [180, 184]. Natalizumab works by disrupting the VLA4–VCAM-1 interaction, preventing the migration of lymphocytes and monocytes into the CNS [185]. BTK inhibitors indirectly target EBV by inhibiting B-cell signaling pathways the virus requires for survival [180]. IFN-β may affect EBV-associated MS through its antiviral and immunomodulatory effects [186]. Also, it affects B lymphocytes by increasing levels of apoptotic markers, including Annexin V and active caspase-3, leading to the death of memory B cells [187]. There is a clear need to investigate targeting EBV with antiviral medications to halt latent-lytic cycling or eliminate latent virus from the body. The fact that MS patients have no control over EBV infection leads us to believe that antivirals acting on the periphery, deep tissue, and CNS will be necessary, in addition to targeting the lytic and latent cycles of EBV infection [180]. In healthy people, effector memory cells make up the majority of EBV-specific T lymphocytes in the blood and CSF. The CSF of MS patients, on the other hand, contains EBV-specific central memory T cells, suggesting that these cells were either primed or recently exposed to EBV antigens, most likely in the CNS. These immune data indicate that the CNS should be the target of antiviral therapies [69]. However, unlike MS DMTs, antiviral therapies may intersect with MS pathogenesis through different mechanisms. Firstly, by reducing viral load or preventing lytic “flares,” antivirals reduce the number of viral antigens available to prime these cross-reactive B and T cells, as evidenced by antibodies in MS patients’ spinal fluid that bind both EBNA1 and GlialCAM [67, 188]. Secondly, antiviral therapies suppress lytic reactivation in B cells. EBV resides permanently in memory B-cells. In MS patients, this latency appears dysregulated, leading to frequent “micro-reactivations” (the lytic phase) [63, 189]. Finally, antiviral therapies lead to a reduction in bystander activation. Chronic EBV infection in the CNS may cause a localized inflammatory “storm.” This environment recruits autoreactive T cells that wouldn’t normally cause damage through a process called bystander activation. This can be evidenced by decreased viral presence in the CNS (intrathecal EBV) and by lowered cytokine levels (such as IFN-γ and IL-17) that fuel these MS lesions [190]. The infection rate was higher among MS patients treated with DMTs such as GA, IFN-β1, fingolimod, natalizumab, and rituximab than in the general population [191]. Furthermore, compared with GA and IFN-β1, the anti-CD20 antibody rituximab was associated with a significantly higher risk of overall severe infection in MS patients. Also, MS patients receiving alemtuzumab, an anti-CD52 antibody, had more HSV infections than those receiving IFN-β1 [191, 192]. Progressive multifocal leukoencephalopathy (PML) has been reported in patients with MS who are treated with DMT, particularly dimethyl fumarate (DMF). Nine documented cases of PML in MS patients treated with DMF exist, and the estimated incidence is 0.02 cases per 1,000 patients. This represents a 3-fold lower risk of PML than with fingolimod and a 100-fold lower risk than with natalizumab [193]. It is hypothesized that DMF triggers PML by decreasing lymphocyte counts and promoting an anti-inflammatory response, resulting in persistent lymphopenia and the reactivation of the John Cunningham Virus (JCV), the causative agent of PML [193]. COVID-19 risks and disease-modifying therapies in MS patients MS affects the CNS by causing inflammation, disruption of the BBB, and autoreactivation of lymphocytes [164]. Recent evidence showed that patients with MS have a lower risk of COVID-19 infection than the general population, but they have a higher risk of hospitalization [194]. Age, male sex, obesity, cardiac comorbidities, and use of anti-CD20 therapies were reported as risk factors for COVID-19 severity [195]. It was hypothesized that DMTs may increase the risk of COVID-19 due to their immunosuppressive properties [196]. For instance, Januel and his colleagues demonstrated that anti-CD20 therapies were associated with severe COVID-19 infection in patients with RRMS by impairing the development of a sufficient antibody response against SARS-CoV-2 [197, 198]. Others postulated that DMTs might reduce a cytokine storm-like immune response or enhance the expression of circulating NK cells, thereby protecting against COVID-19 [199–201]. Therefore, DMTs and immunosuppression did not worsen COVID-19 outcomes among MS patients, except for anti-CD20 therapy. Furthermore, MS patients reported symptoms similar to those of the general population, with no increased risk of neurological complications [202–204]. Other viral infections and disease-modifying therapies in MS patients More recently, other viruses have been observed among MS patients and may be involved in the pathogenesis of the disease. For instance, the link between measles and MS was extensively studied over the years, and it was suggested that MS may be an immune response triggered by measles infection. Also, increased anti-measles antibodies were detected in the CSF and serum of MS patients, depending on age and disease duration [205, 206]. Human Endogenous Retroviruses (HERVs) are replication-defective retroviral proviruses strongly associated with MS, and several SNPs in regions surrounding HERV-encoded RNAs were linked to RRMS and progressive MS [207, 208]. Furthermore, it was suggested that members of the Gammaretrovirus HERV family, HERV-H and HERV-W, are causal in MS [209, 210]. High levels of HERV-W have been detected in the brains and sera of MS patients [211, 212]. Moreover, HERV-W levels increased during disease relapses and decreased during remission, with higher antibody reactivity against their epitopes observed during relapse [213]. An established body of evidence indicates that increased HERV-W expression is linked to immune activation and inflammation [214]. The HERV-W epitopes expressed by active B cells and monocytes have also been shown to cross-react with myelin proteins through molecular mimicry [215]. HERV-W inhibits oligodendrocyte precursor cell formation and remyelination in the brain, damaging myelinated axons in MS patients [216, 217]. Interestingly, the autoimmune mechanism of HERVs could be induced by dual infection with other viruses implicated in MS pathogenesis, such as HSV-1, HHV-6, VZV, or EBV, which may trigger HERV reactivation [218, 219]. Antiretroviral therapy and MS The literature has previously reported the association between antiretroviral therapy and MS. A case of a 35-year-old woman with both MS and human immunodeficiency virus (HIV) had only one disease relapse after receiving combined antiretroviral therapy (cART) despite irregular or no MS therapy [220]. In a Danish epidemiological study on patients with HIV, investigators found that the rate ratio of MS was 0.38 (95%CI; 0.15 to 0.79) compared to individuals without HIV [221]. The investigators hypothesized their findings with two explanations. First, HIV infection could lower immunity and impair the immunological signals required for MS pathogenesis. Second, ART may suppress other viral infections, such as herpes, suspected to be implicated in the disease’s pathogenesis [221]. Moreover, a similarity between the FDA-approved MS drug dimethyl fumarate and the fumaric acid found in certain antiretroviral medications, such as tenofovir, may be a rationale for the improvement of MS in HIV-positive individuals [221]. It is still challenging to determine if the amount of fumaric acid used is enough to treat MS. According to other studies, antiretroviral treatments function by upregulating T regulatory cells (Treg), as Treg downregulation in MS contributes to CNS damage through autoreactive CD4 + T lymphocytes [222, 223]. Efavirenz reduces the expression of MS-related HERVs, which are abundantly expressed among MS patients [224]. Moreover, the administration of multiple antiretroviral medications mimicking highly active antiretroviral therapy (HAART) resulted in a greater reduction in HERVs, suggesting that HAART’s protective effect against MS might be mediated by its synergistic action [224]. Environmental and preventive factors influencing ms development and relapses Association between infections and MS relapses Several studies have shown a temporal relationship between acute systemic infections and an increased relapse rate in patients with MS, often accompanied by the appearance of contrast-enhancing lesions on MRI [225, 226]. Furthermore, infections are recognized as the main trigger of pseudo-relapse, defined as a clinical episode presenting signs and symptoms similar to those observed in a previous relapse but in the absence of new inflammatory activity, among MS patients [227]. Among various infectious triggers, upper respiratory tract viral infections, including influenza-like illnesses, have been most consistently linked to MS exacerbations. VZV reactivation has also been associated with increased relapse rate in some patients, particularly with immunomodulatory therapies [225, 228, 229]. In contrast, not all viruses implicated in MS pathogenesis show a consistent association with relapse occurrence. For example, EBV is strongly associated with MS pathogenesis and disease progression; however, EBV serostatus or viral antigen detection does not strongly correlate with the timing of MS relapses [230]. Similarly, the presence of viral DNA or antibodies in serum or CSF does not always coincide with clinical or radiological activity of MS. However, a significant correlation between the B cell response to CMV and MS disease activity was found in relapse and remission [230]. Evidence suggests that infectious agents may act as indirect triggers rather than a direct cause of MS relapses. Systemic infections can induce immune activation, cytokine release, and transient disruption of the BBB, thereby facilitating the reactivation of autoreactive immune responses within the CNS [231]. Viral infections may disrupt BBB integrity through different mechanisms, including direct neurotropism, the Trojan-horse mechanism via infected macrophages or free virions, or systemic infection and inflammation [232]. This bystander effect may precipitate relapses independently of direct viral neuroinvasion or antigen-specific immune responses. Such observations support the rationale for preventive strategies, including vaccination against common infectious agents, to reduce infection-related disease outcomes, potentially stabilize disease activity in MS patients, and enhance the immune response against such infections. Safety and recommendations for vaccination in MS patients A study of 643 MS patients in the MS European Database found that routine vaccinations, including hepatitis B, influenza, and tetanus, did not increase the risk of relapse [233]. Most vaccinations, particularly tetanus plus diphtheria or poliomyelitis, were associated with a low risk of relapse [233, 234]. Likewise, no relapses were recorded in Netherlands among 180 patients in the Groningen MS Database six weeks after tetanus vaccination [235]. Also, a meta-analysis of cohort and case-control studies concluded that the tetanus vaccine was associated with a low risk of developing MS, with an OR of 0.67 [236]. Some vaccinations could trigger autoimmunity and aggravate MS by molecular mimicry and the activation of bystander T lymphocytes [237]. However, a meta-analysis of 144 studies reported an equivalent occurrence of autoimmune disorders in vaccinated and unvaccinated individuals, thus confirming that common vaccinations are not a cause of any associated autoimmune disorders [238]. Vaccinations with post-vaccine follow-up are recommended for MS patients [234, 239]. The practice guidelines, including those from the National Institute for Health and Care Excellence (NICE) and the MS Council in the US, suggest applying national vaccination standards to MS patients [240, 241]. However, vaccine immunogenicity and effectiveness differ across DMT classes, with reduced responses reported in patients receiving B-cell–depleting therapies, S1P receptor modulators, and some high-efficacy immunosuppressive agents. While patients on interferons, glatiramer acetate, or fumarates typically have higher vaccine responses [242, 243]. Therefore, vaccine timing, type (live vs. inactivated), and post-vaccination monitoring should be individualized according to the specific DMT class. Vaccine indications and contraindications in MS patients are similar to those in healthy subjects, yet there is insufficient data about specific vaccinations recommended for MS. Impact of viral infection on vitamin D and MS development Vitamin D plays a pivotal role in MS pathogenesis, including in virus-related MS. One possible mechanism by which vitamin D can lessen the severity of cytokine storms is by decreasing the production of cytokines that promote inflammation. In addition to enhancing the body’s natural defenses against viruses, vitamin D also promotes the synthesis of peptides that fight microbes [244]. The immune system, cell proliferation, differentiation, and hormone release are all regulated mainly by vitamin D. Many immune cells have receptors for it, and immune cells also produce its active metabolite, which confers immunomodulatory function [245]. Vitamin D also promotes the production of powerful antibacterial peptides, such as cathelicidin and β-defensin 2, which are expressed in neutrophils, monocytes, NK cells, and epithelial cells lining the respiratory tract [246, 247]. Vitamin D also controls the synthesis of RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), a naturally occurring ligand of CCR5 that aids in the blocking of viral entrance [248]. Vitamin D and cathelicidin levels were positively correlated in critically ill patients [249]. Evidence of a favorable correlation between vitamin D status and plasma LL-37 levels suggests that vitamin D status controls systemic LL-37 levels. Optimum vitamin D levels may play a role in innate immunity, particularly in sepsis [249]. Vitamin D blood levels above 50 nmol/L are believed necessary for this immune system advantage to materialize, with 75–80 nmol/L considered ideal [250]. The Vitamin D receptor (VDR) is a crucial regulator of the immune response to viral infections, mediating the effects of Vitamin D3 to induce antiviral states, curb viral replication, and modulate inflammation [251]. The VDR is essential for the transcription of genetic information from DNA to messenger RNA, thereby controlling cellular development, the immune response, and other critical physiological functions [252, 253]. The expression of these antimicrobial peptides is enhanced upon stimulation by 25(OH)D via VDRs in macrophages, lymphocytes, and monocytes [254]. The EBV converts B cells into immortalized lymphoblasts. A VDR protein was identified as a binding partner of EBV nuclear antigen 3 (EBNA-3), a member of the EBNA-3 protein family that modulates the transcription of both cellular and viral genes. This protein inhibits the activation of VDR-dependent genes and safeguards lymphoblast cell lines against vitamin D3-induced growth arrest and apoptosis [255]. Maintaining adequate vitamin D levels in the blood may be one strategy to prevent EBV from re-emerging and causing illness, according to one study [256]. Because EBV proteins might inhibit VDR function, it is wise to replenish vitamin D stores as soon as possible. The innate immune system triggers an immediate response by activating the toll receptor, which, in turn, induces cathelicidin, a vitamin D3-dependent protein [255, 257]. A case-control study by Maghzi et al. showed that mean Vitamin D levels were lower among patients with infectious mononucleosis than among healthy controls [258]. These results further support an association between MS development and Vitamin D. In a randomized controlled trial by Rolf et al., Vitamin D3 supplementation effectively reduced antibody levels against EDNA-1 in the intervention group. However, EBV load and cytotoxic T cell response remained unaffected [259]. Moreover, the risk of developing MS increases twofold in the case of early-life obesity due to decreased vitamin D levels among obese subjects [260]. Impact of smoking on viral infection and MS development Smoking has not only been associated with a higher risk of MS development but has also been associated with rapid disease progression and poor outcomes [261]. Current and past smokers have higher levels of EBNA-1 antigen than non-smokers [262]. Compared to smokers, non-smokers have a high amount of anti-EBV antibodies as well as a greater viral load of the EBV [263]. Cigarette smoking increases the risk of MS much more with increased intensity and duration of smoking, especially among men [261, 264]. Also, smoking has been linked to the reactivation of EBV infection, thereby increasing the risk of MS development and progression [265, 266]. Novel techniques for demonstrating viruses In MS MS is characterized by increased production of IgG antibodies in both CSF and the brain; therefore, the target antigens can be detected by molecular analysis [267]. Many studies focus on peripheral blood mononuclear cells (PBMCs) because they are readily obtained from blood samples. Inspecting changes in the transcriptomic profile of PBMCs in MS patients is an optimal way to identify potential altered networks and the gene expression patterns following specific treatments [268]. However, the most intriguing immune components are found in the CNS. Thus, to study MS, one effective method is to visualize IgG OCBs in CSF using isoelectric focusing gels. A challenge, however, is obtaining samples at multiple time points [268]. Furthermore, viral DNA is often undetected in the CSF of patients with MS, with a prevalence that is not significantly higher than in controls, suggesting the absence of viral DNA in the CNS or CSF and cell trafficking from the periphery, rather than leakage through the BBB, results in the transport of viruses to the CNS [269–272]. Previously, IgG cloning has revealed sequences of heavy chains expressed at various plaque locations in the CSF and brain [273]. Hence, further analysis of the IgG specificity is warranted to detect the infectious agents of MS. Tschochner et al. have confirmed the feasibility of directly extracting DNA from buffy coat samples for analysis of EBNA-1 sequences. This method has revealed several immunogenic regions of EBNA-1, along with known and novel targets for autoreactive HLA-DRB1*15-restricted T cells in the CNS, which may result from cross-reactivity with EBNA-1-specific immune responses [274]. Quantitative PCR (qPCR) has traditionally been regarded as the gold standard for the absolute quantification of target nucleic acids. However, the accuracy of viral load quantification using qPCR relies on extrapolation from a standard calibration curve, which can lead to significant inter-assay variability. Additionally, accurately measuring viral load can be challenging, especially in samples with low cell counts, such as CSF. Consequently, qPCR may not be the best method for quantifying viral load, particularly given the need for consistency and reliability in detecting biologically relevant thresholds and changes [275, 276]. Recent studies have shown that droplet-based digital PCR (ddPCR) does not require a standard calibration curve, unlike qPCR. Furthermore, the high sensitivity of ddPCR for detecting and quantifying clinically relevant pathogens is particularly valuable, especially when nucleic acid quantities are very low. A recent study of MS patients found equal precision between qPCR and ddPCR, with greater viral-detection sensitivity in favor of ddPCR. ddPCR also demonstrated superior efficacy and sensitivity for detecting CMV, EBV, HSV, and HHV-6 compared with qPCR, highlighting its potential role in viral detection in CFS patients with MS [275, 276]. Metagenomic next-generation sequencing (mNGS) is a high-throughput sequencing technology that can detect any pathogen without requiring sequence-specific amplification. This approach addresses the limitations of traditional pathogen-specific PCR tests, facilitating the rapid identification of unknown pathogens. mNGS has successfully identified a variety of pathogens in patients with CNS infections that were previously tested negative by conventional methods, demonstrating greater sensitivity than these traditional techniques [277]. Limited studies have investigated the values of mNGS among MS patients and reported the detection of GB virus-C (GBV-C or hepatitis G virus), EBV, CMV, HHV-6, VZV, and parvovirus in CSF, highlighting that further studies are needed to determine the sensitivity of this technique for viral detection among patients with MS [271, 278, 279]. Single-nucleus RNA sequencing (snRNA-seq) can be used to stratify patients with MS. Analysis of snRNA-seq data has shown that molecular changes in the grey matter of MS patients are linked to the presence of demyelinated lesions. In contrast, the changes observed in the white matter are more complex and vary across patients. The gene expression patterns identified in white matter lesions revealed four distinct neurodegenerative pathological patterns in MS. These include an increase in pathways related to protein folding, chaperones, and ubiquitination; an elevated inhibitory ECM response affecting oligodendroglial differentiation; an alternative cross-glial response to DNA damage; and an immune response from oligodendrocytes that indicates a failure in the final stages of oligodendrocyte maturation [280]. These changes may serve as biomarkers for the accurate detection, stratification, and treatment selection of MS patients. Future studies would benefit from integrating multi-omics approaches, including genomics (DNA), epigenomics, transcriptomics (RNA), proteomics (proteins), and immunophenotyping, to better understand how host–virus interactions affect MS disease [281, 282]. Such strategies may help disentangle causal relationships from secondary immune activation, identify virus-specific molecular signatures within the CNS, and clarify how genetic susceptibility, environmental exposures, and viral infections contribute to MS disease onset and progression. Thus, it will help to transform our understanding of this heterogeneous, complex autoimmune disease from a “one-approach-fits-all” to personalized, precision medicine. Conclusion This review focused on the roles of various viral infections in MS, such as EBV, CMV, VZV, HSV-1, HHV-6, WNV, and, more recently, SARS-CoV-2. We observed that these viruses modulate the neuro-immunological system, which may be associated with immune-mediated demyelination through molecular mimicry and the activation of immune responses, inflammation, and autoimmunity. Additionally, latent viral infections with multiple reactivation episodes might be associated with relapsing MS. However, there is insufficient evidence to support a causal association between viruses and MS pathogenesis. Meanwhile, recent studies have shown that SARS-CoV-2 vaccines strengthen both humoral and cell-mediated immune responses in patients with MS, while DMTs did not worsen COVID-19 outcomes among them. Moreover, novel treatments for MS focusing on B-cell-depleting antibodies (including antiviral therapy), reducing MS severity and relapses, are emerging. Conversely, vitamin D deficiency, smoking, and obesity were associated with an increased risk of developing MS. Understanding the etiology of MS and the role of viruses in its physiopathology may enable more targeted interventions and, thus, better outcomes. Acknowledgements None. Author contributions Study idea: Mostafa Meshref and Hossam Younis; Original draft writing and literature search: Ahmed Salah Hussein and Sahar Ahmed Allam; Visualization and graphic presentation: Ahmed Salah Hussein, Sahar Ahmed Allam, and Khaled Moghib; Project Administration: Ahmed Salah Hussein; Manuscript revision and supervision: Ahmed Salah Hussein, Nevin Shalaby, and Mostafa Meshref, Draft approval for submission: All authors. Funding No funding was received for conducting this study. Data availability All data generated or presented in this study are included in this article. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mostafa Meshref and Ahmed Salah Hussein contributed equally to this work. References Associated Data Data Availability Statement All data generated or presented in this study are included in this article.